249 related articles for article (PubMed ID: 2153395)
21. Oestrogen receptor and oestrogen regulated proteins in human breast cancer: a review.
Henry JA; Angus B; Horne CH
Keio J Med; 1989 Sep; 38(3):241-61. PubMed ID: 2685440
[TBL] [Abstract][Full Text] [Related]
22. Effects of the antioestrogen, ICI 164,384, on oestrogen induced RNAs in MCF-7 cells.
Wiseman LR; Wakeling AE; May FE; Westley BR
J Steroid Biochem; 1989 Jul; 33(1):1-6. PubMed ID: 2761257
[TBL] [Abstract][Full Text] [Related]
23. In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients.
Licznerska BE; Wegman PP; Nordenskjöld B; Wingren S
Breast Cancer Res Treat; 2008 Nov; 112(1):15-23. PubMed ID: 18030614
[TBL] [Abstract][Full Text] [Related]
24. In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer.
Maudelonde T; Escot C; Pujol P; Rouanet P; Defrenne A; Brouillet JP; Rochefort H
Eur J Cancer; 1994; 30A(14):2049-53. PubMed ID: 7857701
[TBL] [Abstract][Full Text] [Related]
25. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
Anderson ED; Forrest AP; Levack PA; Chetty U; Hawkins RA
Br J Cancer; 1989 Aug; 60(2):223-6. PubMed ID: 2527549
[TBL] [Abstract][Full Text] [Related]
26. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
27. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
28. Isolation and characterization of an oestrogen-responsive breast-cancer cell line, EFF-3.
Healicon RM; Westley BR; May FE
Int J Cancer; 1993 Feb; 53(3):388-94. PubMed ID: 8428792
[TBL] [Abstract][Full Text] [Related]
29. Activated oestrogen receptors in breast cancer and response to endocrine therapy.
Fernandez MD; Burn JI; Sauven PD; Parmar G; White JO; Myatt L
Eur J Cancer Clin Oncol; 1984 Jan; 20(1):41-6. PubMed ID: 6537914
[TBL] [Abstract][Full Text] [Related]
30. The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer.
Manning DL; McClelland RA; Gee JM; Chan CM; Green CD; Blamey RW; Nicholson RI
Eur J Cancer; 1993; 29A(10):1462-8. PubMed ID: 8398276
[TBL] [Abstract][Full Text] [Related]
31. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
32. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
Jirström K; Rydén L; Anagnostaki L; Nordenskjöld B; Stål O; Thorstenson S; Chebil G; Jönsson PE; Fernö M; Landberg G
J Clin Pathol; 2005 Nov; 58(11):1135-42. PubMed ID: 16254100
[TBL] [Abstract][Full Text] [Related]
33. [Estrogen receptor status of breast cancer patients].
Winzer KJ; Saul G; Sinn B; Kranz D; Wolff H; Rose H
Zentralbl Chir; 1986; 111(15):915-20. PubMed ID: 3020841
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen therapy, oestrogen receptor status, and postmenopausal breast cancer.
A'Hern RP; Wilson AJ; Baum M
Lancet; 1985 Apr; 1(8435):976. PubMed ID: 2859424
[No Abstract] [Full Text] [Related]
35. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
[TBL] [Abstract][Full Text] [Related]
36. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
Clarke RB; Laidlaw IJ; Jones LJ; Howell A; Anderson E
Br J Cancer; 1993 Mar; 67(3):606-11. PubMed ID: 8439511
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
38. Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells.
May FE; Westley BR
Cancer Res; 1986 Dec; 46(12 Pt 1):6034-40. PubMed ID: 2430688
[TBL] [Abstract][Full Text] [Related]
39. Progesterone and oestrogen receptors in human breast cancer.
Holdaway IM; Mountjoy KG
Aust N Z J Med; 1978 Dec; 8(6):630-8. PubMed ID: 285684
[TBL] [Abstract][Full Text] [Related]
40. Oestrogen receptors and prognosis in early breast cancer.
Cooke T; George D; Shields R; Maynard P; Griffiths K
Lancet; 1979 May; 1(8124):995-7. PubMed ID: 86771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
